| scholarly article | Q13442814 |
| P50 | author | Steven J Korzeniewski | Q61097173 |
| Tinnakorn Chaiworapongsa | Q69022472 | ||
| Lami Yeo | Q88230658 | ||
| Roberto Romero | Q42734915 | ||
| P2093 | author name string | Piya Chaemsaithong | |
| P2860 | cites work | Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia | Q56619493 |
| An integrative review of the side effects related to the use of magnesium sulfate for pre-eclampsia and eclampsia management | Q21261344 | ||
| Magnesium sulphate and other anticonvulsants for women with pre-eclampsia | Q24236438 | ||
| Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems | Q24236570 | ||
| Drugs for treatment of very high blood pressure during pregnancy | Q24244908 | ||
| Antiplatelet agents for preventing pre-eclampsia and its complications | Q24245285 | ||
| Magnesium sulphate and other anticonvulsants for women with pre-eclampsia | Q24248655 | ||
| Researching new methods of screening for adverse pregnancy outcome: lessons from pre-eclampsia | Q26824297 | ||
| Accuracy of circulating placental growth factor, vascular endothelial growth factor, soluble fms-like tyrosine kinase 1 and soluble endoglin in the prediction of pre-eclampsia: a systematic review and meta-analysis | Q26825271 | ||
| Angiogenic factors in preeclampsia: potential for diagnosis and treatment | Q26825774 | ||
| Aspirin in the prevention of pre-eclampsia in high-risk women: a randomised placebo-controlled PREDO Trial and a meta-analysis of randomised trials | Q26828468 | ||
| If we know so much about preeclampsia, why haven't we cured the disease? | Q27009441 | ||
| Angiogenic factors in diagnosis, management, and research in preeclampsia | Q27692060 | ||
| Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data | Q28211057 | ||
| Soluble endoglin contributes to the pathogenesis of preeclampsia | Q28244053 | ||
| Mapping the theories of preeclampsia and the role of angiogenic factors: a systematic review | Q28281326 | ||
| Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia | Q29615916 | ||
| Performance of the fullPIERS model in predicting adverse maternal outcomes in pre-eclampsia using patient data from the PIERS (Pre-eclampsia Integrated Estimate of RiSk) cohort, collected on admission | Q30573957 | ||
| Soluble fms-Like Tyrosine Kinase 1 (sFlt1), Endoglin and Placental Growth Factor (PlGF) in Preeclampsia among High Risk Pregnancies | Q30990384 | ||
| Preeclampsia and anaesthesia | Q33383867 | ||
| Pre-eclampsia part 1: current understanding of its pathophysiology | Q33416340 | ||
| Prediction of pre-eclampsia by an analysis of placenta-derived cellular mRNA in the blood of pregnant women at 15-20 weeks of gestation | Q33528109 | ||
| Recombinant vascular endothelial growth factor 121 infusion lowers blood pressure and improves renal function in rats with placentalischemia-induced hypertension | Q33666742 | ||
| Maternal plasma concentrations of angiogenic/antiangiogenic factors in the third trimester of pregnancy to identify the patient at risk for stillbirth at or near term and severe late preeclampsia | Q33863973 | ||
| Can changes in angiogenic biomarkers between the first and second trimesters of pregnancy predict development of pre-eclampsia in a low-risk nulliparous patient population? | Q33923716 | ||
| Prospective evaluation of ultrasound and biochemical-based multivariable models for the prediction of late pre-eclampsia | Q56983816 | ||
| Gene expression in chorionic villous samples at 11 weeks of gestation in women who develop pre-eclampsia later in pregnancy: implications for screening | Q56986820 | ||
| Calcium supplementation to prevent hypertensive disorders of pregnancy | Q57226506 | ||
| Angiogenic factors combined with clinical risk factors to predict preterm pre-eclampsia in nulliparous women: a predictive test accuracy study | Q58035948 | ||
| Correction to "Magee LA, Helewa M, Moutquin J-M, von Dadelszen P. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy. J Obstet Gynaecol Can 2008;30(Suppl 1):S17." | Q58623907 | ||
| Diagnosis, Evaluation, and Management of the Hypertensive Disorders of Pregnancy | Q58623909 | ||
| Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia | Q58778301 | ||
| Free fetal DNA is not increased before 20 weeks in intrauterine growth restriction or pre-eclampsia | Q58825399 | ||
| Uterine artery Doppler at 11 + 0 to 13 + 6 weeks and 21 + 0 to 24 + 6 weeks in the prediction of pre-eclampsia | Q61826567 | ||
| Maternal Plasma Cell-Free Fetal and Maternal DNA at 11-13 Weeks' Gestation: Relation to Fetal and Maternal Characteristics and Pregnancy Outcomes | Q61847818 | ||
| Maternal serum placental protein 13 at 11â 13 weeks of gestation in preeclampsia | Q61847857 | ||
| Recombinant vascular endothelial growth factor 121 attenuates hypertension and improves kidney damage in a rat model of preeclampsia | Q64377002 | ||
| Hypertension in pregnancy: clinical-pathological correlations and remote prognosis | Q70803180 | ||
| Which anticonvulsant for women with eclampsia? Evidence from the Collaborative Eclampsia Trial | Q72285628 | ||
| CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group | Q72669570 | ||
| First trimester maternal serum free beta human chorionic gonadotrophin and pregnancy associated plasma protein A as predictors of pregnancy complications | Q73070066 | ||
| Increased maternal plasma fetal DNA concentrations in women who eventually develop preeclampsia | Q73371440 | ||
| Trial of Calcium to Prevent Preeclampsia | Q73485563 | ||
| Nifedipine in pregnancy | Q73599957 | ||
| Labor induction for the preterm severe pre-eclamptic patient: is it worth the effort? | Q77313754 | ||
| Microalbuminuria after pregnancy complicated by pre-eclampsia | Q77799245 | ||
| First-trimester maternal serum PP-13, PAPP-A and second-trimester uterine artery Doppler pulsatility index as markers of pre-eclampsia | Q79409207 | ||
| Mechanistic and epidemiologic considerations in the evaluation of adverse birth outcomes following gestational exposure to statins | Q81012782 | ||
| Prediction of pregnancy complications by first-trimester maternal serum PAPP-A and free beta-hCG and with second-trimester uterine artery Doppler | Q81020289 | ||
| Angiogenic factors for the prediction of preeclampsia in high-risk women | Q81160614 | ||
| Use of circulating antiangiogenic factors to differentiate other hypertensive disorders from preeclampsia in a pregnant woman on dialysis | Q81212660 | ||
| Case records of the Massachusetts General Hospital. Case 38-2005. A 29-year-old pregnant woman with the nephrotic syndrome and hypertension | Q81627640 | ||
| Serum inhibin A and angiogenic factor levels in pregnancies with previous preeclampsia and/or chronic hypertension: are they useful markers for prediction of subsequent preeclampsia? | Q81931106 | ||
| A novel approach to first-trimester screening for early pre-eclampsia combining serum PP-13 and Doppler ultrasound | Q82068160 | ||
| Circulating angiogenic factors in preeclampsia, gestational proteinuria, and preeclampsia superimposed on chronic glomerulonephritis | Q82470256 | ||
| Prediction of preeclampsia by analysis of cell-free messenger RNA in maternal plasma | Q83351931 | ||
| Comprehensive maternal serum proteomic profiles of preclinical and clinical preeclampsia | Q84455834 | ||
| Superimposed preeclampsia in women with chronic kidney disease | Q84669343 | ||
| Application of a first-trimester prediction model for pre-eclampsia based on uterine arteries and maternal history in high-risk pregnancies | Q84669850 | ||
| Placental protein-13 and pregnancy-associated plasma protein-A as first trimester screening markers for hypertensive disorders and small for gestational age outcomes | Q84719535 | ||
| Angiogenic biomarkers for prediction of maternal and neonatal complications in suspected preeclampsia | Q84724037 | ||
| Hypertension in pregnancy: the NICE guidelines | Q85077918 | ||
| Evaluation and management of severe preeclampsia before 34 weeks' gestation | Q34070992 | ||
| Plasma concentrations of angiogenic/anti-angiogenic factors have prognostic value in women presenting with suspected preeclampsia to the obstetrical triage area: a prospective study | Q34119026 | ||
| Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy | Q34379583 | ||
| Plasma concentrations of soluble endoglin versus standard evaluation in patients with suspected preeclampsia | Q34461130 | ||
| Placental growth factor for the prediction of adverse outcomes in patients with suspected preeclampsia or intrauterine growth restriction | Q34500006 | ||
| Adenoviral delivery of VEGF121 early in pregnancy prevents spontaneous development of preeclampsia in BPH/5 mice | Q34517776 | ||
| Pravastatin induces placental growth factor (PGF) and ameliorates preeclampsia in a mouse model | Q34533751 | ||
| Cell-free mRNA concentrations of CRH, PLAC1, and selectin-P are increased in the plasma of pregnant women with preeclampsia | Q34635362 | ||
| Clinical practice. Prenatal screening for aneuploidy | Q34986134 | ||
| Effect of supplementation during pregnancy with L-arginine and antioxidant vitamins in medical food on pre-eclampsia in high risk population: randomised controlled trial | Q35002508 | ||
| Placental volume and vascular flow assessed by 3D power Doppler and adverse pregnancy outcomes | Q35076106 | ||
| Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia | Q35871381 | ||
| Diagnosis, prevention, and management of eclampsia | Q36026219 | ||
| Supplementation with vitamins C and E during pregnancy for the prevention of preeclampsia and other adverse maternal and perinatal outcomes: a systematic review and metaanalysis | Q36050839 | ||
| Maternal plasma concentrations of angiogenic/anti-angiogenic factors are of prognostic value in patients presenting to the obstetrical triage area with the suspicion of preeclampsia | Q36062460 | ||
| A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia | Q36189562 | ||
| Should cervical favourability play a role in the decision for labour induction in gestational hypertension or mild pre-eclampsia at term? An exploratory analysis of the HYPITAT trial | Q36230294 | ||
| Chronic kidney disease in pregnancy | Q36405423 | ||
| Low placental growth factor across pregnancy identifies a subset of women with preterm preeclampsia: type 1 versus type 2 preeclampsia? | Q36626307 | ||
| Cost and resource implications with serum angiogenic factor estimation in the triage of pre-eclampsia | Q37097779 | ||
| Clinical characterization and outcomes of preeclampsia with normal angiogenic profile | Q37098433 | ||
| The soluble VEGF receptor sFlt1 contributes to endothelial dysfunction in CKD. | Q37367745 | ||
| Pravastatin for the prevention of preeclampsia in high-risk pregnant women | Q37432893 | ||
| First-trimester maternal serum PP13 in the risk assessment for preeclampsia. | Q37444801 | ||
| Transplacental transfer and distribution of pravastatin | Q37478894 | ||
| The perinatal implications of angiogenic factors | Q37649388 | ||
| Preeclampsia and future maternal health | Q37751739 | ||
| Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. | Q37776132 | ||
| Abnormal placentation, angiogenic factors, and the pathogenesis of preeclampsia | Q37777854 | ||
| Long-term complications of preeclampsia | Q37832329 | ||
| Evaluation of 7 serum biomarkers and uterine artery Doppler ultrasound for first-trimester prediction of preeclampsia: a systematic review | Q37901092 | ||
| Screening for pre-eclampsia: a systematic review of tests combining uterine artery Doppler with other markers. | Q37919093 | ||
| Review: Biochemical markers to predict preeclampsia | Q37971237 | ||
| The promise of angiogenic markers for the early diagnosis and prediction of preeclampsia | Q37995181 | ||
| Early administration of low-dose aspirin for the prevention of severe and mild preeclampsia: a systematic review and meta-analysis | Q38001972 | ||
| Candidate biochemical markers for screening of pre-eclampsia in early pregnancy | Q38019358 | ||
| Calcium supplementation and prevention of preeclampsia: a meta-analysis | Q38034275 | ||
| Cardiovascular disease risk in women with pre-eclampsia: systematic review and meta-analysis | Q38080492 | ||
| Toxemia: new concepts in an old disease | Q39559348 | ||
| Urinary proteomics for prediction of preeclampsia | Q39797354 | ||
| The relationship between calcium intake and edema-, proteinuria-, and hypertension-getosis: an hypothesis | Q40292400 | ||
| Hypertension in pregnancy: the incidence of underlying renal disease and essential hypertension | Q40646788 | ||
| Calcium supplementation during pregnancy may reduce preterm delivery in high-risk populations | Q41181078 | ||
| Preeclampsia: an imbalance in placental prostacyclin and thromboxane production | Q41489416 | ||
| Pharmacokinetic changes during pregnancy and their clinical relevance | Q41657026 | ||
| Dietary calcium supplementation and prevention of pregnancy hypertension | Q44227224 | ||
| A higher maternal choline intake among third-trimester pregnant women lowers placental and circulating concentrations of the antiangiogenic factor fms-like tyrosine kinase-1 (sFLT1). | Q44827166 | ||
| First-trimester metabolomic detection of late-onset preeclampsia | Q45328904 | ||
| Diagnostic accuracy of placental growth factor in women with suspected preeclampsia: a prospective multicenter study | Q45747422 | ||
| Preeclampsia and the risk of end-stage renal disease | Q45748808 | ||
| Management of gestational hypertension - the impact of HYPITATa | Q46044492 | ||
| A competing risks model in early screening for preeclampsia | Q46277645 | ||
| Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11-13 weeks | Q46321423 | ||
| Chronic kidney disease may be differentially diagnosed from preeclampsia by serum biomarkers | Q46322344 | ||
| Prediction of adverse maternal outcomes in pre-eclampsia: development and validation of the fullPIERS model | Q46328960 | ||
| Robust early pregnancy prediction of later preeclampsia using metabolomic biomarkers | Q46329980 | ||
| Induction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia after 36 weeks' gestation (HYPITAT): a multicentre, open-label randomised controlled trial. | Q46333378 | ||
| Stroke and severe preeclampsia and eclampsia: a paradigm shift focusing on systolic blood pressure | Q46345137 | ||
| Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial | Q46351253 | ||
| Maternal serum soluble endoglin at 30-33 weeks in the prediction of preeclampsia. | Q46505791 | ||
| Circulating angiogenic factors and the risk of preeclampsia | Q47217679 | ||
| Cell-free fetal DNA (SRY locus) concentration in maternal plasma is directly correlated to the time elapsed from the onset of preeclampsia to the collection of blood | Q47816303 | ||
| Two-stage elevation of cell-free fetal DNA in maternal sera before onset of preeclampsia. | Q47889241 | ||
| Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award | Q48348609 | ||
| Guidelines for the management of hypertensive disorders of pregnancy 2008. | Q48421837 | ||
| Competing risks model in early screening for preeclampsia by biophysical and biochemical markers. | Q51331330 | ||
| Metabolomics and first-trimester prediction of early-onset preeclampsia. | Q51383635 | ||
| Committee Opinion no. 514: emergent therapy for acute-onset, severe hypertension with preeclampsia or eclampsia. | Q51493232 | ||
| Soluble Fms-like tyrosine kinase associated with preeclampsia in pregnancy in systemic lupus erythematosus. | Q53497854 | ||
| Angiogenic biomarkers for prediction of early preeclampsia onset in high-risk women. | Q54406971 | ||
| Longitudinal evaluation of predictive value for preeclampsia of circulating angiogenic factors through pregnancy. | Q54483574 | ||
| Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia. | Q54570213 | ||
| Performance of messenger RNAs circulating in maternal blood in the prediction of preeclampsia at 10-14 weeks. | Q54644655 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pre-eclampsia | Q61335 |
| P304 | page(s) | 531-540 | |
| P577 | publication date | 2014-07-08 | |
| P1433 | published in | Nature Reviews Nephrology | Q2079275 |
| P1476 | title | Pre-eclampsia part 2: prediction, prevention and management | |
| P478 | volume | 10 |
| Q47099319 | Abnormal CYP11A1 gene expression induces excessive autophagy, contributing to the pathogenesis of preeclampsia |
| Q36357099 | Biomarker development for presymptomatic molecular diagnosis of preeclampsia: feasible, useful or even unnecessary? |
| Q64905439 | Combination of Genetic Markers and Age Effectively Facilitates the Identification of People with High Risk of Preeclampsia in the Han Chinese Population. |
| Q36024649 | Effects of simvastatin, rosuvastatin and pravastatin on soluble fms-like tyrosine kinase 1 (sFlt-1) and soluble endoglin (sENG) secretion from human umbilical vein endothelial cells, primary trophoblast cells and placenta |
| Q35547367 | Endocan, a putative endothelial cell marker, is elevated in preeclampsia, decreased in acute pyelonephritis, and unchanged in other obstetrical syndromes |
| Q35824650 | Epigenetics and Preeclampsia: Defining Functional Epimutations in the Preeclamptic Placenta Related to the TGF-β Pathway |
| Q57300007 | Excessive Neutrophil Activity in Gestational Diabetes Mellitus: Could It Contribute to the Development of Preeclampsia? |
| Q46309172 | Expectant management of severe preterm preeclampsia: a comparison of maternal and fetal indications for delivery. |
| Q40402667 | Failure of physiologic transformation of spiral arteries, endothelial and trophoblast cell activation, and acute atherosis in the basal plate of the placenta. |
| Q33794472 | Gestational Diabetes Mellitus Is Associated with Altered Neutrophil Activity |
| Q28067095 | Gestational weight gain and medical outcomes of pregnancy |
| Q64235245 | Global gene expression analysis of cell-free RNA in amniotic fluid from women destined to develop preeclampsia |
| Q40049011 | Helicobacter pylori infection and risk of preeclampsia: a systematic review and meta-analysis |
| Q64251327 | Human Genetic Adaptation to High Altitude: Evidence from the Andes |
| Q64089847 | Increased expression and phosphorylation of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase isoforms in urinary exosomes in pre-eclampsia |
| Q36034800 | Influence of the sFlt-1/PlGF Ratio on Clinical Decision-Making in Women with Suspected Preeclampsia |
| Q34312652 | Insights into the Role of Helicobacter pylori Infection in Preeclampsia: From the Bench to the Bedside |
| Q58795465 | Integrated Systems Biology Approach Identifies Novel Maternal and Placental Pathways of Preeclampsia |
| Q49243157 | Is an episode of suspected preterm labor that subsequently leads to a term delivery benign? |
| Q92962644 | Is urinary excretion of plasminogen associated with development of pre-eclampsia? An observational, explorative case-control study |
| Q41033848 | Maternal plasma angiogenic index-1 (placental growth factor/soluble vascular endothelial growth factor receptor-1) is a biomarker for the burden of placental lesions consistent with uteroplacental underperfusion: a longitudinal case-cohort study |
| Q40367971 | Maternal plasma-soluble ST2 concentrations are elevated prior to the development of early and late onset preeclampsia - a longitudinal study |
| Q38634773 | Measuring high-altitude adaptation |
| Q39376655 | Metformin, the aspirin of the 21st century: its role in gestational diabetes mellitus, prevention of preeclampsia and cancer, and the promotion of longevity |
| Q35214428 | MiR-519d-3p suppresses invasion and migration of trophoblast cells via targeting MMP-2. |
| Q47546216 | Placental Basement Membrane Proteins are Required for Effective Cytotrophoblast Invasion in a 3D Bioprinted Placenta Model |
| Q33416340 | Pre-eclampsia part 1: current understanding of its pathophysiology |
| Q36343649 | Prediction of Preeclampsia by First Trimester Combined Test and Simple Complete Blood Count Parameters |
| Q38543855 | Pulsatility index in combination with biomarkers or mean arterial pressure for the prediction of pre-eclampsia: Systematic literature review and meta-analysis |
| Q64069474 | Role of mammalian target of rapamycin signaling pathway in regulation of fatty acid oxidation in a preeclampsia-like mouse model treated with pravastatin |
| Q55165896 | Seasonal variation in the prevalence of preeclampsia. |
| Q36104833 | Systematic Review of Micro-RNA Expression in Pre-Eclampsia Identifies a Number of Common Pathways Associated with the Disease |
| Q88721038 | Ten-eleven translocation 2 demethylates the MMP9 promoter, and its down-regulation in preeclampsia impairs trophoblast migration and invasion |
| Q36981696 | The atrial natriuretic peptide (ANP) knockout mouse does not exhibit the phenotypic features of pre-eclampsia or demonstrate fetal growth restriction |
| Q38436237 | The maternal plasma proteome changes as a function of gestational age in normal pregnancy: a longitudinal study |
| Q47645647 | The prediction of fetal death with a simple maternal blood test at 20-24 weeks: a role for angiogenic index-1 (PlGF/sVEGFR-1 ratio). |
| Q38664824 | The prediction of late-onset preeclampsia: Results from a longitudinal proteomics study |
| Q49312791 | The use of angiogenic biomarkers in maternal blood to identify which SGA fetuses will require a preterm delivery and mothers who will develop pre-eclampsia |
Search more.